Effects of fibrates on serum lipids and atherosclerosis.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Pharmacology and Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0163-7258(88)90024-1PMID 3290906
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.

  2020cited by this paper
• Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

  2009cited by this paper
• Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects

  2004cited by this paper
• Regulation of the biosynthesis of two distinct fatty acid-binding proteins in rat liver and intestine. Influences of sex difference and of clofibrate.

  1985cited by this paper
• Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins.

  1985cited by this paper
• Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.

  1985cited by this paper
• Effects of fenofibrate on biliary lipids and bile acid pool size in patients with type IV hyperlipoproteinemia.

  1985cited by this paper
• Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects.

  1985cited by this paper
• Mechanism of action of gemfibrozil on lipoprotein metabolism.

  1985cited by this paper
• Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. Normalization with bezafibrate therapy.

  1985cited by this paper
• Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia.

  1985cited by this paper
• Effects of storage on the distribution of high density lipoprotein subfractions in human sera.

  1985cited by this paper
• Mechanisms of action of absorbable hypolipidemic drugs.

  1985cited by this paper
• The effect of etophylline clofibrate on HDL subfractions.

  1985cited by this paper
• Lipoprotein substrates for plasma cholesterol esterification. Influence of particle size and composition of the high density lipoprotein subfraction 3.

  1985cited by this paper
• DNA damage related to increased hydrogen peroxide generation by hypolipidemic drug-induced liver peroxisomes.

  1984cited by this paper
• Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.

  1984cited by this paper
• Gas chromatographic determination of gemfibrozil and its metabolites in plasma and urine.

  1984cited by this paper
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

  1984cited by this paper
• Effect of fenofibrate on serum lipoproteins in subjects with familial hypercholesterolemia and combined hyperlipidemia.

  1984cited by this paper
• Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.

  1984cited by this paper
• Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.

  1984cited by this paper
• High density lipoprotein metabolism.

  1984cited by this paper
• Effect of short‐term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia

  1984cited by this paper
• Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia

  1984cited by this paper
• Interpretation of clofibrate trial.

  1984cited by this paper
• Influence of Gemfibrozil and Clofibrate on Metabolism of Cholesterol and Plasma Triglycerides in Man

  1984cited by this paper
• Novel pyrimidine and 1,3,5-triazine hypolipidemic agents.

  1984cited by this paper
• The origin and properties of free cholesterol potential gradients in plasma, and their relation to atherogenesis.

  1984cited by this paper
• Effect of fenofibrate and LF 2151 on hepatic peroxisomes in hamsters.

  1984cited by this paper
• Interpretation of clofibrate trial.

  1984cited by this paper
• Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man.

  1983cited by this paper
• Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial.

  1983cited by this paper
• Evaluation of Selected Hypolipidemic Agents for the Induction of Peroxisomal Enzymes and Peroxisome Proliferation in the Rat Liver

  1983cited by this paper
• Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease.

  1983cited by this paper
• Measurement of Atherosclerosis by Arteriography and Microdensitometry: Model and Clinical Investigations

  1983cited by this paper
• Perturbation by clofibrate of mitochondrial levels in animal cells. Implications for a model of mitochondrial genesis.

  1982cited by this paper
• Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease.

  1982cited by this paper
• Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.

  1982cited by this paper
• Regression of computer estimated femoral atherosclerosis after pronounced serum lipid lowering in patients with asymptomatic hyperlipidaemia.

  1982cited by this paper
• Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial.

  1982cited by this paper
• Increased Apoprotein B in Very Low Density Lipoproteins of Patients with Peripheral Vascular Disease

  1982cited by this paper
• High-density Lipoprotein Subfractions in Normolipidemic Patients with Coronary Atherosclerosis

  1982cited by this paper
• Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.

  1982cited by this paper
• Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects.

  1982cited by this paper
• Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.

  1982cited by this paper
• Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.

  1982cited by this paper
• Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.

  1982cited by this paper
• HEPATIC AND RENAL EFFECTS OF PEROXISOME PROLIFERATORS: BIOLOGICAL IMPLICATIONS *

  1982cited by this paper
• Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.

  1982cited by this paper
• Long-term treatment of type III hyperlipoproteinemia with clofibrate.

  1981cited by this paper
• Clofibrate treatment and bile cholesterol saturation: short‐term and long‐term effects and influence of combination with chenodeoxycholic acid

  1981cited by this paper
• Serum triglycerides, to be or not to be a risk factor for ischaemic heart disease?

  1981cited by this paper
• Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia.

  1981cited by this paper
• Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.

  1981cited by this paper
• Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.

  1981cited by this paper
• Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.

  1981cited by this paper
• Gemfibrozil--the effect of biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate.

  1981cited by this paper
• Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.

  1981cited by this paper
• Mechanism of action of clofibrate.

  1981cited by this paper
• Plasma lipid concentrations and lecithin:cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol.

  1981cited by this paper
• Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins.

  1981cited by this paper
• [The effect of bezafibrate on biliary lipids (author's transl)].

  1980cited by this paper
• Lipoprotein lipase: some effects of activator proteins.

  1980cited by this paper
• Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver.

  1980cited by this paper
• Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease.

  1980cited by this paper
• Mechanism of the hypolipemic effect of clofibrate in glucose-fed men.

  1980cited by this paper
• Characterization of human high density lipoproteins by zonal ultracentrifugation.

  1980cited by this paper
• Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins].

  1980cited by this paper
• Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague-Dawley rats.

  1980cited by this paper
• Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.

  1980cited by this paper
• Superoxide dismutase: correlation with life-span and specific metabolic rate in primate species.

  1980cited by this paper
• Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens

  1980cited by this paper
• The influence of clofibrate on lipid and protein components of very low density lipoproteins in type IV hyperlipoproteinaemia.

  1980cited by this paper
• Biliary and plasma lipids and lipid-lowering chemotherapy Studies with clofibrate, fenofibrate and etofibrate in healthy volunteers

  1980cited by this paper
• Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.

  1980cited by this paper
• The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.

  1980cited by this paper
• Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.

  1980cited by this paper
• Uricosuric Effect of Fenofibrate in Healthy Volunteers

  1980cited by this paper
• Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers

  1980cited by this paper
• Clofibrate raises plasma apoprotein A-I and HDL-cholesterol concentrations.

  1980cited by this paper
• Platelet Kinetic Studies in Patients with Hyperlipoproteinemia: Effects of Clofibrate Therapy

  1979cited by this paper
• Type III hyperlipoproteinemia: rise in high-density lipoprotein levels in response to therapy.

  1979cited by this paper
• Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen.

  1979cited by this paper
• Effects of etofibrate, clofibrate and nicotinic acid on lipid metabolism in hyperlipidemic rats.

  1979cited by this paper
• Clofibrate disposition in renal failure and acute and chronic liver disease

  1979cited by this paper
• A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate.

  1979cited by this paper
• Blood levels, tissue distribution and the duration of action in rats of ciprofibrate, a new hypolipidemic agent.

  1979cited by this paper
• Disposition pharmacokinetics of bezafibrate in man

  1979cited by this paper
• Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K1.

  1979cited by this paper
• Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction.

  1979cited by this paper
• Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis.

  1979cited by this paper
• Influence of procetofen on lipid metabolism in normocholesteremic rats.

  1979cited by this paper
• Are apolipoproteins better discriminators than lipids for atherosclerosis?

  1979cited by this paper
• A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.

  1978cited by this paper
• Effect of Wy-14,643 on cholesterol metabolism in normal and hypercholesterolemic rats.

  1978cited by this paper
• Ballot of consultants and registrars

  1978cited by this paper
• Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers.

  1978cited by this paper
• Morphological effects of moderate diet and clofibrate on swine atherosclerosis.

  1978cited by this paper
• Metabolic effects of clofibrate in insulin-dependent ketosis-prone diabetic man.

  1978cited by this paper

• Molecular Interactions between NAFLD and Xenobiotic Metabolism

  2013cites this paper
• Genomic aspects of NAFLD pathogenesis.

  2013cites this paper
• Fenofibrate decreases radiation sensitivity via peroxisome proliferator-activated receptor α-mediated superoxide dismutase induction in HeLa cells

  2012cites this paper
• Synthesis and biological evaluation of ester prodrugs of Benzafibrate as orally active hypolipidemic agents.

  2012cites this paper
• Regulation of high‐density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease

  2010cites this paper
• Ginger extract and polaprezinc exert gastroprotective actions by anti‐oxidant and growth factor modulating effects in rats

  2010cites this paper
• Fatty Acids Bind Directly to and Activate Peroxisome Proliferator‐activated Receptors α and γ

  2009cites this paper
• Glucose Tolerance, Lipids, and GLP‐1 Secretion in JCR:LA‐cp Rats Fed a High Protein Fiber Diet

  2008cites this paper
• Structure and function of eritadenine and its 3-deaza analogues: potent inhibitors of S-adenosylhomocysteine hydrolase and hypocholesterolemic agents.

  2007cites this paper
• The role of PPARalpha and growth hormone in hepatic lipid metaboism and atherosclerosis

  2006cites this paper
• PPARα activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes Published, JLR Papers in Press, November 10, 2005.

  2006cites this paper
• n-3 Fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance 1 3

  2005cites this paper
• PPARs IN THE REGULATION OF GENE EXPRESSION AND LIPID METABOLISM IN THE LIVER Ulrika Edvardsson

  2005cites this paper
• Peroxisome proliferator-activated receptor alpha (PPARalpha) activators induce hepatic farnesyl diphosphate synthase gene expression in rodents.

  2004cites this paper
• Biochemical and Molecular Actions of Nutrients The Subunit from Soybean 7S Globulin Lowers Plasma Lipids and Upregulates Liver -VLDL Receptors in Rats Fed a Hypercholesterolemic Diet

  2004cites this paper
• Peroxisome proliferator-activated receptor α (PPARα) activators induce hepatic farnesyl diphosphate synthase gene expression in rodents

  2004cites this paper
• The alpha' subunit from soybean 7S globulin lowers plasma lipids and upregulates liver beta-VLDL receptors in rats fed a hypercholesterolemic diet.

  2004cites this paper
• PPAR ligands for metabolic disorders.

  2003cites this paper
• Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists.

  2002cites this paper
• Dietary oxidized fatty acids may enhance intestinal apolipoprotein A-I production.

  2002cites this paper
• Modulation of cytosolic phospholipase A(2) by PPAR activators in human preadipocytes.

  2001cites this paper
• Regulation of lipid metabolism and gene expression by fenofibrate in hamsters.

  2001cites this paper
• Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients.

  2000cites this paper
• High density lipoprotein, apolipoprotein A-1, and coronary artery disease

  2000cites this paper
• Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety

  2000cites this paper
• Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemias.

  1999cites this paper
• The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways.

  1999cites this paper
• Summary Perturbation of developmental gene expression in rat liver by fibric acid derivatives : lipoprotein lipase and-fetoprotein as models

  1999cites this paper
• Effects of hypolipemic therapy on the pharmacokinetics of propranolol

  1999cites this paper
• Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.

  1998cites this paper
• Fatty acids bind directly to and activate peroxisome proliferator-activated receptors alpha and gamma.

  1998cites this paper
• One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations.

  1998cites this paper
• Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity.

  1997cites this paper
• Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ

  1997cites this paper
• N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study.

  1997cites this paper
• Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma.

  1997cites this paper
• Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

  1996cites this paper
• Transcriptional Suppression of the Transferrin Gene by Hypolipidemic Peroxisome Proliferators (*)

  1996cites this paper
• Protein-DNA Interactions at a Drug-responsive Element of the Human Apolipoprotein A-I Gene*

  1996cites this paper
• Novel lipid-lowering properties of Vaccinium myrtillus L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate.

  1996cites this paper
• Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

  1996cites this paper
• HDL heterogeneity and atherosclerosis.

  1996cites this paper
• [Pleiotrophic peroxisome induction by hypolipidemic agents in primates and rodents].

  1996cites this paper
• Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids.

  1995cites this paper
• Effects of gemfibrozil on plasma lipoproteins, plasma activities of hepatic enzymes, and hemostatic variables in hypertriglyceridemic patients

  1995cites this paper
• Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia.

  1995cites this paper
• Comparative effects of clofibrate on peroxisomal enzymes of human (Hep EBNA2) and rat (FaO) hepatoma cell lines.

  1995cites this paper
• Treatment with omega-3 fatty acid ethyl esters in hyperlipoproteinaemias: comparative studies on lipid metabolism and thrombotic indexes.

  1995cites this paper
• Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.

  1995cites this paper
• Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.

  1995cites this paper
• Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction.

  1995cites this paper
• Fibrates: Modes of Action

  1995cites this paper
• Effect of ciprofibrate in patients with primary hypercholesterolemia: a 6-year pilot study

  1995cites this paper
• Re-evaluation of a biguanide, metformin: mechanism of action and tolerability.

  1994cites this paper
• Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element.

  1994cites this paper
• Drug control of reverse cholesterol transport.

  1994cites this paper
• Pharmacological control of hypertriglyceridemia

  1993influential citation
• Thyromimetic effect of peroxisome proliferators.

  1993cites this paper
• Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation.

  1993cites this paper
• Fraudulent (and non fraudulent) fatty acids for human health

  1993cites this paper
• Lipoprotein structure in male subjects during in vivo lipolysis: effect of an anti-lipolytic treatment with acipimox.

  1993cites this paper
• Dose-related increase of HDL-cholesterol levels after N-acetylcysteine in man.

  1993cites this paper
• Influences of lipid-modifying agents on hemostasis

  1993cites this paper
• Drugs Affecting Thrombosis and Atherosclerosis

  1993cites this paper
• Effects of gemfibrozil on the activities of plasma lipolytic enzymes in normolipidemic subjects.

  1993cites this paper
• Lipoprotein structure in male subjects vivo lipolysis: effect of an anti-lipolytic with acipimox during in treatment

  1993cites this paper
• Mode of action of fibrates.

  1992cites this paper
• Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models.

  1992cites this paper
• Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat.

  1992cites this paper
• Down-regulation of hepatic lipase gene expression and activity by fenofibrate.

  1992cites this paper
• Comparative evaluation of fibric acid derivatives and HMG-CoA reductase inhibitors

  1992cites this paper
• Olive oil, corn oil, and n-3 fatty acids differently affect lipids, lipoproteins, platelets, and superoxide formation in type II hypercholesterolemia.

  1992cites this paper
• Drugs Affecting HDL/Triglyceride Levels

  1992cites this paper
• Drugs in the Management of Lipid Disorders

  1991cites this paper
• Reverse cholesterol transport: physiology and pharmacology.

  1991cites this paper
• Management of hypertriglyceridemic patients. D. Pharmacologic management of hypertriglyceridemic patients.

  1991cites this paper
• 7. Management of hypertriglyceridemic patients

  1991cites this paper
• Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents.

  1990cites this paper
• The induction of adipose conversion by bezafibrate in 3T3-L1 cells. Synergism with dibutyryl-cAMP.

  1990cites this paper
• Differential effects of beclobrate on lipid/lipoprotein distribution in normal and hypercholesterolemic rats.

  1990cites this paper
• Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.

  1989cites this paper
• The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.

  1989cites this paper
• Chapter 16. Treatment of Hypercholesterolemia

  1989cites this paper